Compare ResMed Inc. (RMD) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Xylem, Inc. — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Xylem, Inc. trades at $107.96 (market cap $25.41B). The key difference: ResMed Inc. is the larger of the two by market cap, and Xylem, Inc. pays the higher dividend (1.58%). Which is the better fit depends on your goals.
| RMD | XYL | |
|---|---|---|
Market Cap | $31.89B | $25.41B |
Sector | Health | Industrials |
52-Week High | $283.28 | $152.95 |
52-Week Low | $182.82 | $105.69 |
Enterprise Value | $31.24B | $27.18B |
Dividend Yield | 1.19% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Xylem (XYL) trades at $108.81, up 2.95% in the last session, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.46 exceeding expectations. Revenue growth has been steady, rising from $5.5B in 2022 to $9.0B in 2025, while net income margins improved to 10.59%. Recent corporate actions include a dividend declaration and strategic acquisitions to bolster its industrial presence.
The outlook for XYL is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Upside potential is supported by a consensus price target of $152.29, implying significant appreciation. Risks include execution of recent acquisitions and macroeconomic pressures on industrial demand. The stock presents a compelling opportunity for long-term investors focused on water infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
